VIR took a big hit in July with the failure of the company's trial in influenza, but the stock has continued to slide since ... are expected in Q4'23. Vir Biotechnology (NASDAQ:VIR) is a biotech ...

The normally high-flying biotechnology sector is scuffling this ... SBIO's weighting methodology that indicate the fund's recent slide could be a buying opportunity for bold investors.